New perspectives for maximizing sustainable bioethanol production from corn stover

In Egypt, the production of second-generation bioethanol from agricultural waste is a thriving method to compensate the excessive usage as a consequence of the outspread of Covid-19. The profusion and renewability of lignocellulosic biomass urge its utilization as a promising feedstock for bioethanol production. However, functional delignification without affecting the cellulose matrices remains the major obstacle to achieving effective enzyme accessibility. This paper highlights a novel physio-chemical combination for corn stover (CS) pretreatment for bioethanol production. The optimum pretreatment condition was achieved using a mixture of 5% maleic acid (MA) and 3% citric acid (CA) for 30 min at an autoclave temperature of 110 °C leading to produce a pretreated CS (MAC) with 99% hemicellulose removal, 90% cellulose recovery, and 80% lignin removal. Characteristics analyses such as;SEM, FTIR, TGA, EDX, elemental, proximate, ultimate, higher heating value (HHV), and functionalization analyses were performed to emphasize the property and structure change of CS before and after the pretreatment. Then, MAC was hydrolyzed by cellulase enzyme and produced 13.5 g/L glucose yield which was fermented by Saccharomyces cerevisiae and produced 10 g/L bioethanol. [Display omitted] [ FROM AUTHOR] Copyright of Renewable Energy: An International Journal is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

AMICOUMACIN-BASED PRODRUG DEVELOPMENT APPROACH

Coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, is highly contagious and has a severe morbidity. Providing care to patients with COVID-19 requires the development of new types of antiviral drugs. The aim of this work is to develop a prodrug for the treatment of coronavirus disease using the antibiotic Amicoumacin A (Ami), the mechanism of action of which is based on translation inhibition. Enzymatic hydrolysis of an inactivated prodrug by the SARS-CoV-2 main protease can lead to the release of the active Ami molecule and, as a consequence, the suppression of protein biosynthesis in infected cells. To test the proposed hypothesis, a five-stage synthesis of an inactivated analogue of Amicoumacin A was carried out. Its in vitro testing with the SARS-CoV-2 recombinant protease MPro showed a low percentage of hydrolysis. Further optimization of the peptide fragment of the inactivated analog recognized by the SARS-CoV-2 MPro protease may lead to an increase in proteolysis and the release of Amicoumacin A.